首页> 外文期刊>European urology >Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy
【24h】

Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy

机译:CAPRA-S评分的多机构验证可预测前列腺癌根治术后的疾病复发和死亡率

获取原文
获取原文并翻译 | 示例
           

摘要

Background The University of California, San Francisco, Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score uses pathologic data from radical prostatectomy (RP) to predict prostate cancer recurrence and mortality. However, this clinical tool has never been validated externally. Objective To validate CAPRA-S in a large, multi-institutional, external database. Design, setting, and participants The Shared Equal Access Regional Cancer Hospital (SEARCH) database consists of 2892 men who underwent RP from 2001 to 2011. With a median follow-up of 58 mo, 2670 men (92%) had complete data to calculate a CAPRA-S score. Intervention RP. Outcome measurements and statistical analysis The main outcome was biochemical recurrence. Performance of CAPRA-S in detecting recurrence was assessed and compared with a validated postoperative nomogram by concordance index (c-index), calibration plots, and decision curve analysis. Prediction of cancer-specific mortality was assessed by Kaplan-Meier analysis and the c-index. Results and limitations The mean age was 62 yr (standard deviation: 6.3), and 34.3% of men had recurrence. The 5-yr progression-free probability for those patients with a CAPRA-S score of 0-2, 3-5, and 6-10 (defining low, intermediate, and high risk) was 72%, 39%, and 17%, respectively. The CAPRA-S c-index was 0.73 in this validation set, compared with a c-index of 0.72 for the Stephenson nomogram. Although CAPRA-S was optimistic in predicting the likelihood of being free of recurrence at 5 yr, it outperformed the Stephenson nomogram on both calibration plots and decision curve analysis. The c-index for predicting cancer-specific mortality was 0.85, with the caveat that this number is based on only 61 events. Conclusions In this external validation, the CAPRA-S score predicted recurrence and mortality after RP with a c-index >0.70. The score is an effective prognostic tool that may aid in determining the need for adjuvant therapy.
机译:背景技术加利福尼亚大学旧金山分校的前列腺癌手术后风险评估(CAPRA-S)评分使用来自根治性前列腺切除术(RP)的病理数据来预测前列腺癌的复发和死亡率。但是,该临床工具从未得到外部验证。目的在大型,多机构的外部数据库中验证CAPRA-S。设计,地点和参与者共享均等访问区域癌症医院(SEARCH)数据库由2001年至2011年接受过RP的2892名男性组成。平均随访58个月,有2670名男性(占92%)拥有完整的数据可以计算CAPRA-S分数。干预RP。结果测量和统计分析主要结果是生化复发。评估CAPRA-S在检测复发方面的性能,并通过一致性指数(c-index),校准图和决策曲线分析与经过验证的术后列线图进行比较。通过Kaplan-Meier分析和c指数评估癌症特异性死亡率的预测。结果与局限性平均年龄为62岁(标准差:6.3),其中34.3%的男性复发。 CAPRA-S评分为0-2、3-5和6-10(定义了低,中和高风险)的患者的5年无进展机率分别为72%,39%和17% , 分别。在该验证集中,CAPRA-S c指数为0.73,而Stephenson列线图的c指数为0.72。尽管CAPRA-S乐观地预测5年后不会复发,但在校正图和决策曲线分析上,它均优于Stephenson诺模图。预测癌症特异性死亡率的c指数为0.85,但请注意,该数字仅基于61个事件。结论在此外部验证中,CAPRA-S评分预测了RP后的复发和死亡率,c指数> 0.70。评分是有效的预后工具,可帮助您确定是否需要辅助治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号